文献速递肿瘤 PET/CT

一种预测多种转移性肿瘤FDG摄取的新型基因组特征

A novel genomic signature predicting FDG uptake in diverse metastatic tumors.
PubMed 文献 · EJNMMI Res · 2018-01-18

本研究利用71例多种组织学类型的转移性肿瘤训练集,结合PET/CT定量与全人类基因组基因表达微阵列,构建预测FDG摄取强度的基因组特征。基于与SUVmean35最强关联的909个探针,偏最小二乘三成分模型(PLS-3)在训练集交叉验证中表现最佳(RMSE=0.443),并在独立验证集(n=13)中获得处于训练集95%CI内的性能(RMSE=0.645)。除糖酵解外,核糖体生物合成和DNA复制与较高SUVmean35相关,细胞骨架重组和自噬与较低SUVmean35相关。

要点

  • PLS-3基因组特征可准确预测多种转移性肿瘤的FDG摄取强度。
  • 除糖酵解外,核糖体生物合成和DNA复制与较高SUVmean35相关。
  • 细胞骨架重组和自噬与较低SUVmean35相关。

核心结论

  • PLS-3是一种能准确预测多种转移性肿瘤FDG摄取强度的特征。
  • FDG-PET可能有助于设计针对从SUVmean35及其对抗肿瘤治疗反应变化推断出的更可能在肿瘤中激活的恶性生物学过程的特定靶向治疗。

研究设计与样本

  • 使用平衡训练集(n=71)的转移性肿瘤构建特征,包括一些最常见组织学类型,并配有匹配的PET/CT定量测量和全人类基因组基因表达微阵列。
  • 微阵列特征选择完全基于其与FDG摄取(以SUVmean35测量)的强关联,采用单变量线性回归进行。
  • 对上述基因进行了全面的生物信息学研究,并通过将多种最先进的回归技术拟合到训练集来构建多变量模型以进行比较。
  • 在独立验证数据集(n=13)中进一步验证PLS-3模型。

主要发现

  • 与SUVmean35最强关联的909个探针(包括742个可识别基因和62个未匹配到符号的探针)被用于构建特征。
  • 使用三个成分的偏最小二乘(PLS-3)在训练数据集交叉验证中表现最佳(均方根误差,RMSE=0.443)。
  • PLS-3在独立验证数据集(n=13)中得到进一步验证,获得的性能处于训练数据集所得性能的95%CI内(RMSE=0.645)。
  • 除糖酵解外,与SUVmean35相关的显著过度代表的生物学过程包括核糖体生物合成和DNA复制(与较高SUVmean35相关)以及细胞骨架重组和自噬(与较低SUVmean35相关)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Building a universal genomic signature predicting the intensity of FDG uptake in diverse metastatic tumors may allow us to understand better the biological processes underlying this phenomenon and their requirements of glucose uptake. METHODS: A balanced training set (n = 71) of metastatic tumors including some of the most frequent histologies, with matched PET/CT quantification measurements and whole human genome gene expression microarrays, was used to build the signature. Selection of microarray features was carried out exclusively on the basis of their strong association with FDG uptake (as measured by SUVmean35) by means of univariate linear regression. A thorough bioinformatics study of these genes was performed, and multivariable models were built by fitting several state of the art regression techniques to the training set for comparison. RESULTS: The 909 probes with the strongest association with the SUVmean35 (comprising 742 identifiable genes and 62 probes not matched to a symbol) were used to build the signature. Partial least squares using three components (PLS-3) was the best performing model in the training dataset cross-validation (root mean square error, RMSE = 0.443) and was validated further in an independent validation dataset (n = 13) obtaining a performance within the 95% CI of that obtained in the training dataset (RMSE = 0.645). Significantly overrepresented biological processes correlating with the SUVmean35 were identified beyond glycolysis, such as ribosome biogenesis and DNA replication (correlating with a higher SUVmean35) and cytoskeleton reorganization and autophagy (correlating with a lower SUVmean35). CONCLUSIONS: PLS-3 is a signature predicting accurately the intensity of FDG uptake in diverse metastatic tumors. FDG-PET might help in the design of specific targeted therapies directed to counteract the identified malignant biological processes more likely activated in a tumor as inferred from the SUVmean35 and also from its variations in response to antineoplastic treatments.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Crespo-Jara A, Redal-Peña MC, Martinez-Navarro EM, et al. A novel genomic signature predicting FDG uptake in diverse metastatic tumors. EJNMMI Res. 2018. PMID: 29349517. doi:10.1186/s13550-017-0355-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。